Beijnen JH - Search Results

1

Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.

Kerbusch T, vanPutten JW, Groen HJ, Huitema AD, Mathĵt RA, Beijnen JH. Kerbusch T, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 2001 Jul;48(1):53-61. doi: 10.1007/s002800100277. Cancer Chemother Pharmacol. 2001. PMID: 11488525

2

Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report.

Beijnen JH, Bais EM, ten Bokkel Huinink WW. Beijnen JH, et al. Cancer Chemother Pharmacol. 1994;33(6):523-6. doi: 10.1007/BF00686512. Cancer Chemother Pharmacol. 1994. PMID: 7511066

3

Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

Giaccone G, Huizing M, Postmus PE, ten Bokkel Huinink WW, Koolen M, van Zandwijk N, Vermorken JB, Beijnen JH, Dalesio O, Pinedo HM, et al. Giaccone G, et al. Among authors: beijnen jh. Semin Oncol. 1995 Aug;22(4 Suppl 9):78-82. Semin Oncol. 1995. PMID: 7544030 Clinical Trial.

4

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O, Beijnen JH. Sparreboom A, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 1995;36(4):299-304. doi: 10.1007/BF00689047. Cancer Chemother Pharmacol. 1995. PMID: 7628049

5

High-dose chemotherapy regimens for solid tumors.

van der Wall E, Beijnen JH, Rodenhuis S. van der Wall E, et al. Among authors: beijnen jh. Cancer Treat Rev. 1995 Mar;21(2):105-32. doi: 10.1016/0305-7372(95)90023-3. Cancer Treat Rev. 1995. PMID: 7758003 Review.

6

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 1995;35(3):237-45. doi: 10.1007/BF00686554. Cancer Chemother Pharmacol. 1995. PMID: 7805183 Free article. Clinical Trial.

7

The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Sips JH, van Tellingen O, Nooijen WJ, Rodenhuis S, Ten Bokkel Huinink WJ, Beijnen JH. Sips JH, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 1994;35(2):144-8. doi: 10.1007/BF00686637. Cancer Chemother Pharmacol. 1994. PMID: 7987991

8

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

van Warmerdam LJ, Rodenhuis S, van Tellingen O, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 1994;35(2):179-81. doi: 10.1007/BF00686644. Cancer Chemother Pharmacol. 1994. PMID: 7987998 Clinical Trial.

9

Ifosfamide metabolism and pharmacokinetics (review).

Kaijser GP, Beijnen JH, Bult A, Underberg WJ. Kaijser GP, et al. Among authors: beijnen jh. Anticancer Res. 1994 Mar-Apr;14(2A):517-31. Anticancer Res. 1994. PMID: 8017856 Review.

10

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

Jonkman-de Vries JD, Talsma H, Henrar RE, Kettenes-van den Bosch JJ, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 1994;34(5):416-22. doi: 10.1007/BF00685567. Cancer Chemother Pharmacol. 1994. PMID: 8070009

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,526 results

Search Page

Filters